(NASDAQ: ARVN) Arvinas's forecast annual revenue growth rate of 62.56% is forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 35.36%, and it is also forecast to beat the US market's average forecast revenue growth rate of 9.64%.
Arvinas's revenue in 2024 is $71,300,000.On average, 9 Wall Street analysts forecast ARVN's revenue for 2024 to be $12,436,332,847, with the lowest ARVN revenue forecast at $6,843,189,100, and the highest ARVN revenue forecast at $26,004,118,580. On average, 9 Wall Street analysts forecast ARVN's revenue for 2025 to be $16,583,305,442, with the lowest ARVN revenue forecast at $6,843,189,100, and the highest ARVN revenue forecast at $28,193,939,092.
In 2026, ARVN is forecast to generate $21,010,917,221 in revenue, with the lowest revenue forecast at $15,293,843,320 and the highest revenue forecast at $32,765,189,411.